Attending Physician
Active Chart · MRN SYN-1016
62 y/o M · Hepatic encephalopathy
Encounter timeline and laboratory review
Linked visit history and responsible clinicians.
Hepatic encephalopathy · Dr. Rachel Stone
Started Mar 5, 2026, 7:30 PM
Recent resulted values for the active encounter.
| Collected | Test | Value | Reference |
|---|---|---|---|
| Mar 5, 2026, 7:50 PM | Creatinine | 1.8 mg/dL | 0.7-1.3 |
| Mar 5, 2026, 7:50 PM | Total bilirubin | 4.8 mg/dL | 0.1-1.2 |
| Mar 5, 2026, 7:50 PM | Albumin | 2.1 g/dL | 3.5-5.0 |
| Mar 5, 2026, 7:50 PM | INR | 2.2 | 0.9-1.1 |
| Mar 5, 2026, 7:50 PM | Ammonia | 142 umol/L | 15-45 |
CONSULT · Dr. Y. Tanaka · Mar 5, 2026, 8:30 PM
Decompensated cirrhosis with hepatic encephalopathy grade II-III. Asterixis present. Likely precipitant: medication non-adherence to lactulose. Recommend lactulose titration to 3-4 BM/day and rifaximin.
Progress and clinical documentation
CONSULT · Dr. Y. Tanaka · Mar 5, 2026, 8:30 PM
Decompensated cirrhosis with hepatic encephalopathy grade II-III. Asterixis present. Likely precipitant: medication non-adherence to lactulose. Recommend lactulose titration to 3-4 BM/day and rifaximin.
Medication, lab, and imaging entry
LAB · Mar 5, 2026, 7:40 PM
Parameters: STAT
Rationale: Baseline liver function.
LAB · Mar 5, 2026, 7:40 PM
Parameters: STAT
Rationale: Assess encephalopathy severity.
Finalize documentation and orders
Signing this visit finalizes notes and promotes all remaining draft or pending orders to signed.